Connect with us

Technology

Piramal Pharma Limited Announces Results for Q4 and FY2025

Published

on

MUMBAI, India, May 14, 2025 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31st March 2025.

 

 

Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars

Q4FY25

Q4FY24

YoY Growth

FY25

FY24

YoY Growth

Revenue from Operations

2,754

2,552

8 %

9,151

8,171

12 %

   CDMO

1,788

1,649

8 %

5,447

4,750

15 %

   CHG

705

667

6 %

2,633

2,449

8 %

   ICH

274

238

15 %

1,093

985

11 %

EBITDA

603

556

8 %

1,580

1,372

15 %

EBITDA Margin

22 %

22 %

17 %

17 %

PAT (before exceptional item)

154

132

16 %

91

81

13 %

Exceptional Item*

(31)

NM

(63)

NM

PAT (after exceptional item)

154

101

52 %

91

18

411 %

* Q4FY24 – ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized;
Q3FY24 – ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier

 

Key Highlights for Q4FY25/FY25

Revenue from Operations grew by 8% YoY and 12% YoY in Q4FY25 and FY25 respectively, driven primarily by CDMO business especially from on-patent commercial manufacturingEBITDA grew by 8% YoY and 15% YoY in Q4FY25 and FY25 respectively, on account of operating leverage, cost optimization, and operational excellence initiativesNet-Debt to EBITDA ratio improved to 2.7x Vs. 5.6x in FY23Best-in-Class Quality Track Record – Continue to maintain our ‘Zero OAIs’ status since 2011Sustainability Efforts Yielding Results – Significant enhancement in S&P Global and EcoVadis ESG scores  

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY25 has been a steady year for the company as we crossed $1Bn in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth. During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business.

We believe, we are on track to deliver on our FY2030 aspirations of becoming a $2bn revenue company with 25% EBITDA margins and high teens ROCE.”

 

Key Business Highlights for Q4 and FY2025

Contract Development and Manufacturing Organization (CDMO):

–  Increasing contribution from Innovation1 related work – Up from 50% in FY24 to 54% in FY25, driven by commercial manufacturing of on-patent molecules

–  Robust growth in on-patent commercial manufacturing revenues – Grew by over 50% YoY to reach $179mn (Vs. $116mn in FY24 and $53mn in FY23)

–  Revenues from differentiated offerings grew 28% YoY, contributing to 49% of CDMO revenues

–  Healthy growth in API generics business

–  YoY improvement in EBITDA margin driven by better procurement strategies, cost optimization and operational excellence initiatives

–  Maintained our best-in-class quality track record – Successfully cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations

 

Complex Hospital Generics (CHG):

–  Inhalation Anesthesia (IA) – Major GPO contract renewal and order wins supporting IA sales in the US. Witnessing encouraging traction in the RoW markets

–  Capacity expansion in India completed and commercialized on time; poised to capitalize on ~US$400 mn2 Sevoflurane market opportunity in the RoW markets

–  Maintained our #1 Rank in the US in Sevoflurane (44% market share2) and in intrathecal Baclofen (75% market share2)

–   Received approval for Neoatricon®3 for multiple markets in EU and UK by our partner BrePco Pharma. Neoatricon® is the only pre-diluted, age-appropriate formulation of dopamine, approved for treating children and infants

–  Moderation in EBITDA margins due to some non-recurring expenses and capacity expansion in India. However, recovery expected from FY26 with commercialization of these added capacities

 

India Consumer Healthcare (ICH):

–  ICH business crossed the strategic revenue milestone of ₹ 1,000 crores during the year

–  Power Brands continue to grow strength to strength with 20% YoY during FY25. Power Brands contributed to 49% of total ICH sales

o  Excluding i-range, which was impacted by regulatory price control, growth in power brands was about 26% in FY25

–  New Product Launches – Added 21 new products and 31 new SKUs in FY25

–  Investments in Media and Promotions – 11% of ICH sales in FY25. Launched our new media campaign with Yami Gautam for Little’s

–  E-commerce sales grew at 39% YoY in FY25, contributing 21% to ICH sales,. Present on more than 20 e-commerce platforms

1. Discovery + Development + Commercial Manufacturing of products under patent; 2. As per IQVIA data, September 2024; 3. Neoatricon® is developed by BrePco Biopharma;
we have secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing in these regions. 

 

 

Consolidated Profit and Loss Statement

(in ₹ Crores or as stated)

Particulars

Quarterly

Full Year

Q4FY25

Q4FY24

YoY  Change

FY25

FY24

YoY  Change

Revenue from Operations

2,754

2,552

8 %

9,151

8,171

12 %

Other Income

42

26

59 %

135

175

(23 %)

Total Income

2,796

2,579

8 %

9,286

8,347

11 %

Material Cost

955

1,014

(6 %)

3,232

2,954

9 %

Employee Expenses

612

494

24 %

2,307

2,030

14 %

Other Expenses

626

514

22 %

2,167

1,991

9 %

EBITDA

603

556

8 %

1,580

1,372

15 %

Finance Cost

104

114

(9 %)

422

448

(6 %)

Depreciation

243

196

24 %

816

741

10 %

Share of net profit of associates

16

12

35 %

73

59

23 %

Profit Before Tax

273

258

6 %

415

242

71 %

Tax

119

126

(5 %)

324

161

100 %

Net Profit after Tax (before exceptional item)

154

132

16 %

91

81

13 %

Exceptional item*

(31)

NM

(63)

NM

Net Profit after Tax (after exceptional item)

154

101

52 %

91

18

411 %

* Q4FY24 – ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized;
Q3FY24 – ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier

 

 

Consolidated Balance Sheet

 (In ₹ Crores)

   Key Balance Sheet Items

As at

31-Mar-25

31-Mar-24

Total Equity

8,125

7,911

Net Debt

4,199

3,932

Total

12,324

11,843

Net Fixed Assets

9,110

9,106

    Tangible Assets

4,534

4,250

    Intangible Assets including goodwill

3,599

3,740

    CWIP (including IAUD*)

977

1,116

Net Working Capital

2,798

2,339

Other Assets#

416

398

Total Assets

12,324

11,843

*IAUD – Intangible Assets Under Development

# Other Assets include Investments and Deferred Tax Assets (Net)

 

 

 

Q4FY25/FY25 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 15th May 2025 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and FY25 Results.

The dial-in details for the call are as under:

Event

Location & Time

Telephone Number

Conference call on
15th May, 2025

India – 09:30 AM IST

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

1 800 120 1221 (Toll free number)

USA – 12:00 AM

(Eastern Time – New York)

Toll free number

18667462133

UK – 05:00 AM

(London Time)

Toll free number

08081011573

Singapore – 12:00 PM

(Singapore Time)

Toll free number

8001012045

Hong Kong – 12:00 PM

(Hong Kong Time)

Toll free number

800964448

Express Join with Diamond Pass™

Please use this link for prior registration to reduce wait time at the time of joining the call –https://clicktime.symantec.com/15tTDy8HiefVsfhet88NZ?h=fW3GbZrqogMd-yABQyRMy2isMM11wQD-TSFMQrYI2gs=&u=https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber%3D6099661%26linkSecurityString%3D26cd0b7825 Click Here

 

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

* Includes one facility via PPL’s minority investment in Yapan Bio.

For more information, visit:  Piramal Pharma | LinkedIn

Logo – https://mma.prnewswire.com/media/1855206/4913155/Piramal_Pharma_Limited_Logo.jpg

 

 

                      

View original content:https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-results-for-q4-and-fy2025-302455711.html

SOURCE Piramal Pharma Ltd

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ADX welcomes Morgan Stanley as the first international investment bank Remote Trading Member, expanding global access to Abu Dhabi’s capital markets

Published

on

By

ABU DHABI, UAE, May 5, 2026 /PRNewswire/ — The Abu Dhabi Securities Exchange (ADX) Group today announced that Morgan Stanley, a leading investment bank and financial services company, has joined the ADX as its first international investment bank Remote Trading Member — enabling Morgan Stanley’s clients to access the ADX directly.

This milestone strengthens ADX’s global connectivity and supports growing international institutional demand for exposure to UAE markets. It also reinforces its position as one of the world’s fastest-growing exchanges by market capitalization, while highlighting the market’s continued progress in depth, liquidity, and inclusion in major global indices.

Remote membership enables Morgan Stanley to provide its clients with direct market access to the ADX, with trading conducted via the firm’s global trading platform. The ADX continues to play a pivotal role in advancing Abu Dhabi’s long-term economic ambitions, as a mechanism for a diversified, innovation-led, knowledge-based economy.

Morgan Stanley’s direct trading access to ADX reflects the strength of Abu Dhabi’s investment proposition and the continued institutionalization of UAE capital markets. Morgan Stanley’s membership will enhance execution quality, optimize order routing, and provide greater control across the end-to-end trade lifecycle, delivering an advanced trading experience for global investors.

The structure follows a proven international access model used by Morgan Stanley and is designed to meet growing client demand for efficient, transparent, and seamless access to ADX-listed opportunities.

Abdulla Salem Alnuaimi, Group Chief Executive Officer of Abu Dhabi Securities Exchange (ADX) Group, said: “This marks a significant step in advancing our ambition to be a leading financial marketplace that drives opportunity and sustainable economic growth. This momentum is reflected in the strong foreign investor participation, with trading value exceeding 85 billion dirhams in the first quarter of 2026 up by 22% year on year. This performance underscores the growing depth and global relevance of our market, while reinforcing our commitment to expanding international access, strengthening cross-border connectivity, and building a world-class market infrastructure that attracts global capital, supports a diverse range of issuers and contributes to Abu Dhabi’s long-term economic prosperity.”

Patrick Delivanis, Regional Co-Head of MENA at Morgan Stanley, said: “Becoming a Remote Trading Member of ADX reflects our focus on providing clients with efficient, seamless access to Abu Dhabi’s capital markets through our market–leading trading platform. We see continued momentum in the institutionalization and international participation of UAE markets, and we’re pleased to support that evolution by enabling international investors to access opportunities in MENA with direct connectivity to local markets, alongside greater transparency and control across the trading lifecycle.”

Morgan Stanley’s participation aligns with ADX’s strategy to strengthen international connectivity, with remote memberships selectively offered to global firms to attract high-quality cross-border liquidity. The announcement builds on the ADX’s expansion momentum: in 2025, foreign investment rose by nearly 14% and institutional trading increased by 10% year on year. Subject to final operational readiness, Morgan Stanley expects to begin trading as a remote member in the coming weeks.

About Abu Dhabi Securities Exchange (ADX)

The Abu Dhabi Securities Exchange (ADX) was established on 15 November 2000 pursuant to Local Law No. (3) of 2000, which granted the exchange legal rights with independent financial and administrative status, as well as the necessary supervisory and executive powers necessary to carry out its functions. On 17 March 2020, the ADX was converted from a public entity into a Public Joint Stock Company (PJSC) in accordance with Law No. (8) of 2020.

The ADX Group, a market infrastructure group comprising the exchange (ADX) and its post-trade ecosystem, including its wholly owned subsidiaries AD Depository and AD Clear, was established. Through its integrated and globally aligned business structure, the ADX Group supports efficient, transparent, and resilient capital markets across trading, clearing, settlement, and custody.

The Group provides an efficient and regulated marketplace for the trading of securities, including equities issued by public joint-stock companies, bonds issued by governments and corporations, exchange-traded funds (ETFs), and other financial instruments approved by the UAE Capital Market Authority.

The ADX is the second-largest exchange in the Arab region by market capitalization. Its strategy of delivering stable financial performance through diversified revenue streams is aligned with the UAE’s national development agenda, “Towards the Next 50”, which aims to build a sustainable, diversified, and high-value-added economy.

For more information, please contact:
Abdulrahman Saleh ALKhateeb
Manager of Corporate Communication
Abu Dhabi Securities Exchange (ADX)
Mobile: +971 (50) 668 9733
Email: ALKhateebA@adx.ae

 

 

View original content:https://www.prnewswire.com/apac/news-releases/adx-welcomes-morgan-stanley-as-the-first-international-investment-bank-remote-trading-member-expanding-global-access-to-abu-dhabis-capital-markets-302762404.html

SOURCE Abu Dhabi Securities Exchange (ADX)

Continue Reading

Technology

Geotab integrates Polestar vehicles into its OEM telematics network

Published

on

By

Fleet operators across North America, Europe, and APAC can now access Polestar vehicle data directly in MyGeotab — no aftermarket hardware required.

LONDON, UK, May 5, 2026 /PRNewswire/ — Geotab, a global leader in connected vehicle and asset management solutions, today announced the integration of Polestar vehicles into its OEM telematics network, giving commercial fleet operators seamless access to Polestar data within MyGeotab from day one — with no aftermarket hardware installation required. The integration is available globally across North America, Europe, and Asia Pacific, supporting all Polestar models.

Developed in collaboration with Geotab, among other telematics service providers, Polestar Fleet Telematics integrates directly into MyGeotab. The Geotab integration enables fleet managers to manage Polestar vehicles alongside all other makes and models on a single unified platform — without fitting additional devices.

Connected vehicle data where it matters most

Through Polestar Fleet Telematics, fleet operators gain near-real-time access to a comprehensive dataset — covering EV battery and charging status, location, tyre information, vehicle security, maintenance alerts, and climate data — flowing directly from Polestar’s connected vehicle architecture into MyGeotab, with no physical installation required.

This breadth of data enables fleet managers to move from reactive to proactive operations — scheduling maintenance before failures occur, optimising charge planning across depots, and maintaining duty-of-care oversight across the entire fleet.

Supporting Europe’s Mixed-Fleet Reality

OEM-embedded telematics removes the need for aftermarket device installation across mixed-manufacturer fleets, reducing logistical overhead and supporting compliance with works council and GDPR requirements — a critical consideration for European fleet operators.

“Polestar Fleet Telematics combines sustainability with intelligence, integrating seamlessly with Geotab to deliver these capabilities directly into the platforms fleet operators trust. Continuous data visibility enables more efficient and informed fleet operations, from day-to-day management to long-term planning. By leveraging Polestar vehicles’ embedded connectivity, fleet managers can make smarter, data-driven decisions — without adding hardware or complexity to their operations.” said Emma Knapp, Manager of Global Key Accounts at Polestar.

Polestar joins an OEM telematics network that already spans over 80% of leading global vehicle manufacturers by fleet market share, including BMW Group, Ford, Stellantis, Volkswagen Group, and Volvo Cars. For fleet operators already using MyGeotab, Polestar vehicles can be connected and deliver data without any additional hardware or installation.

“OEM-embedded telematics represents a change in how fleet data reaches the platform — and Polestar’s connected vehicle architecture makes this integration particularly well-suited for markets that are seriously considering transitioning to electric vehicles.” said Christoph Ludewig, Vice President OEM Global at Geotab. “Fleet operators managing mixed EV and internal combustion engine fleets no longer need separate tools or hardware for each vehicle type. Polestar data flows directly into MyGeotab alongside every other vehicle in the fleet — giving operators the consolidated visibility they need to drive efficiency, support duty of care, and manage their EV transition with confidence.”

Global Availability

The integration is available now across North America, Europe, and Asia Pacific, supporting all Polestar models. Fleet managers can activate the service via the Geotab Marketplace or by contacting their Geotab representative.

About Polestar

Polestar (Nasdaq: PSNY) is the Swedish electric performance car brand with a focus on uncompromised design and innovation, and the ambition to accelerate the change towards a sustainable future. Headquartered in Gothenburg, Sweden, its cars are available in 28 markets globally across North America, Europe and Asia Pacific.

Polestar has four models in its line-up: Polestar 2, Polestar 3, Polestar 4, and Polestar 5. Planned models include the Polestar 7 compact SUV (to be introduced in 2028) and the Polestar 6 roadster. With its vehicles currently manufactured on two continents, North America and Asia, Polestar plans to diversify its manufacturing footprint further, with production of Polestar 7 planned in Europe.

Polestar has an unwavering commitment to sustainability and has set an ambitious roadmap to reach its climate targets: halve greenhouse gas emissions by 2030 per-vehicle-sold and become climate-neutral across its value chain by 2040. Polestar’s comprehensive sustainability strategy covers the four areas of Climate, Transparency, Circularity, and Inclusion.

About Geotab

Geotab is a global leader in connected vehicle and asset management solutions, with headquarters in Oakville, Ontario and Atlanta, Georgia. Our mission is to make the world safer, more efficient, and sustainable. We leverage advanced data analytics and AI to transform fleet performance and operations, reducing cost and driving efficiency. Backed by top data scientists and engineers, we serve approximately 100,000 global customers, processing 100 billion data points daily from more than 5 million vehicle subscriptions. Geotab is trusted by Fortune 500 organisations, mid-sized fleets, and the largest public sector fleets in the world, including the US Federal government. Committed to data security and privacy, we hold FIPS 140-3 and FedRAMP authorisations. Our open platform, ecosystem of outstanding partners, and Geotab Marketplace deliver hundreds of fleet-ready third-party solutions. This year, we’re celebrating 25 years of innovation. Learn more at www.geotab.com/uk and follow us on LinkedIn or visit our blog.

GEOTAB and GEOTAB MARKETPLACE are registered trademarks of Geotab Inc. in Canada, the United States and/or other countries.

Media Contact: Geotab Contact, Romina Dashghachian, Strategic Communications Lead, EMEA, pr@geotab.com

Photo – https://mma.prnewswire.com/media/2972188/Geotab_Inc__Geotab_integrates_Polestar_vehicles_into_its_OEM_tel.jpg 
Logo – https://mma.prnewswire.com/media/2972187/Geotab_Inc__Geotab_integrates_Polestar_vehicles_into_its_OEM_tel.jpg 

 

View original content:https://www.prnewswire.co.uk/news-releases/geotab-integrates-polestar-vehicles-into-its-oem-telematics-network-302761910.html

Continue Reading

Technology

IDX Opens Geneva Office and Strengthens Global Data & Insights Capability

Published

on

By

New Swiss presence and specialist team integration support growing global demand for evidence-based, defensible communications strategies

LONDON, May 5, 2026 /PRNewswire/ — IDX today announced the opening of its new Geneva office and the integration of a specialist Data & Insights team, strengthening the company’s international footprint and expanding its ability to help clients worldwide build communications strategies grounded in evidence, market intelligence and audience insight.

The expansion gives IDX an on-the-ground presence in Switzerland while adding further depth to its Data & Insights capability. The Geneva-based team will work closely with IDX specialists across performance marketing and corporate communications, helping clients develop a clearer view of the markets they operate in and the forces shaping their growth.

The move aligns with Destination 250 – Customers First, IDX’s global strategy to grow its team by 250, focused on deepening client value, strengthening delivery and investing in the capabilities that matter most to clients.

The investment strengthens the Data pillar of IDX’s Connected Content™ model, which combines Creative, Data, Technology and Media to create what IDX calls The Multiplier Effect, helping clients multiply what matters through more connected, measurable and effective work.

“IDX is experiencing phenomenal growth, and our new Geneva office gives us boots on the ground to better serve clients across Europe and globally across performance marketing, investor relations and corporate communications,” said Crispin Beale, Worldwide CEO, IDX. “Data has been at the heart of this business for decades, and this centre of excellence reflects our continued investment in that capability. It’s an incredibly exciting time for IDX, and I look forward to the next phase of our growth as we continue to expand globally.”

“This is an exciting step in IDX’s growth story and a clear response to what clients are asking for: more evidence-based thinking, stronger market context and clearer rationale behind their communications strategies,” said Chris Corrigan, Chief Customer Growth Officer, IDX. “Our new presence in Geneva, combined with deeper Data & Insights expertise, strengthens the way we support clients globally, giving them earlier access to the insight and market context they need to make better-informed decisions and turn evidence into action.”

The Geneva office will strengthen relationships with existing clients in the region, support re-engagement with former partners and create new opportunities for IDX with organisations operating across European and global markets. It reflects IDX’s continued investment in the capabilities that matter most to clients as communications, marketing and corporate reputation work become increasingly data-led and commercially accountable.

“IDX’s integrated offer across insights, performance marketing and corporate communications, powered by the combination of human intelligence, advanced technology and AI, represents exactly where the industry is heading,” said Lonneke de Roo, Head of Data & Insights, IDX. “I am delighted to join the business and help clients navigate increasingly complex markets with clearer evidence, sharper insight and more connected strategies.”

ABOUT IDX  

IDX is a global strategic communications and marketing agency, headquartered in London with offices around the world, including New York, London, Phoenix, Helsinki, Gothenburg, Geneva, and Vadodara. Working with more than 1,600 clients across sectors, IDX combines deep industry knowledge with a data-first mindset to help ambitious brands thrive in complex, fast-moving markets. The firm specialises in performance marketing, investor relations, and stakeholder engagement, delivering integrated campaigns that drive meaningful business outcomes. Visit www.idx.inc to learn more.

Logo – https://mma.prnewswire.com/media/2668561/IDX_black_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/idx-opens-geneva-office-and-strengthens-global-data–insights-capability-302762181.html

Continue Reading

Trending